Johnson & Johnson Ordered To Pay $260M In Latest Talc Trial
The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a prepackaged bankruptcy.
FibroGen Stock Is Surging After The Bell: What’s Going On?
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial supply agreement with Regeneron.
Inogen’s Study Demonstrating The Association Of Portable Oxygen Therapy With Decreased Mortality And Increased Cost-Effectiveness Ratio Published In The Journal Pulmonary Therapy
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today shared the results of a study published in the journal Pulmonary Therapy,
FibroGen Inks Clinical Trial Supply Agreement With Regeneron Pharmaceuticals To Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 And FG-3175, In Combination With LIBTAYO In Upcoming Clinical Trials
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175,
Ascendis Pharma To Present New Data And Updated Results From Phase 1/2 IL-Believe Trial At ASCO 2024
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited
Scholar Rock To Present New Data From SRK-181 Phase 1 DRAGON Trial At ASCO 2024 Annual Meeting
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patientsAnalysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling
Johnson & Johnson Announces Results From A Subgroup Analysis Of The Phase 3 CARTITUDE-4 Study Showing CARVYKTI Improved Progression-Free Survival And Deepened Responses Versus Two Standard Therapies For Patients With Functional High-Risk Multiple Myelo…
73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1CHICAGO, June 3, 2024
Johnson & Johnson Announces Data From Phase 3 PERSEUS Study Showing DARZALEX-Based Regimens Significantly Improve Clinical Outcomes In Both Transplant-Eligible And -Ineligible Patients Who Are Newly Diagnosed With Multiple Myeloma
88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and
Structure Therapeutics’ Obesity Candidate Is ‘ Very Competitive’ To Eli Lilly’s Orforglipron, Analyst Says
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target
GSK’s Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or refractory multiple myeloma compared to bortezomib with PomDex.